Is fbio a good buy

Fortress Biotech (FBIO) is not a good buy at this time. Here are the key reasons:

1. Financial Performance: FBIO reported a net loss of $28.82 million and a diluted EPS of -$0.73 for the latest quarter. The company's total revenue was $14.9 million, with a revenue growth rate of 51.39% and a net income growth rate of -14.32%. These figures indicate that the company is currently unprofitable and facing significant revenue and net income declines.

2. Stock Price Movement: The stock's price is trading below its 5-Day, 10-Day, and 20-Day moving averages, which could be a bearish signal. The current stock price is near the resistance level of $1.52, which could indicate weak demand.

3. Recent Private Placement: The company recently priced a registered direct offering and private placements, which could be seen as a negative signal for the company's financial health.
4. Insider Transactions: The President and CEO of the company, Lindsay A. Rosenwald, made a significant purchase of FBIO stock, which could be interpreted as a positive sign. However, it is important to note that this purchase was made at a price of $1.84 per share, which is above the current trading price.

In conclusion, the current financial losses, stock price movement, and market sentiment concerns surrounding Fortress Biotech indicate that it is not a good buy at this time. Investors should exercise caution and consider the high risk associated with the company's current situation.